Lixte Biotechnology Holdings Inc
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,684.68 | 80.43 | -1.04% |
| DAX 40 | 23,516.23 | 255.22 | -1.07% |
| Dow JONES (US) | 42,197.79 | 769.83 | -1.79% |
| FTSE 100 | 8,850.63 | 34.29 | -0.39% |
| HKSE | 23,892.56 | 142.82 | -0.59% |
| NASDAQ | 19,406.83 | 255.66 | -1.30% |
| Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 5,976.97 | 68.29 | -1.13% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,377.00 | 25.66 | -0.75% |